Abstract:Human ClpP protease contributes to mitochondrial protein quality control by degrading misfolded proteins. ClpP is overexpressed in cancers such as acute myeloid leukemia (AML), where its inhibition leads to the accumulation of damaged respiratory chain subunits and cell death. Conversely, hyperactivating ClpP with small-molecule activators, such as the recently-discovered ONC201, disrupts mitochondrial protein degradation and impairs respiration in cancer cells. Despite its critical role in human health, the mechanism underlying the structural and functional properties of human ClpP remain elusive. Notably, human ClpP is paradoxically activated by active-site inhibitors. All available structures of human ClpP published to date are in the inactive compact or compressed states, surprisingly even when ClpP is bound to an activator molecule such as ONC201. Here, we present the first structures of human mitochondrial ClpP in the active extended state, including a pair of structures where ClpP is bound to an active-site inhibitor. We demonstrate that amino acid substitutions in the handle region (A192E and E196R) recreate a conserved salt bridge found in bacterial ClpP, stabilizing the extended active state and significantly enhancing ClpP activity. We elucidate the ClpP activation mechanism, highlighting a hormetic effect where sub-stoichiometric inhibitor binding triggers an allosteric transition that drives ClpP into its active extended state. Our findings link the conformational dynamics of ClpP to its catalytic function and provide high-resolution structures for the rational design of potent and specific ClpP inhibitors, with implications for targeting AML and other disorders with ClpP involvement.

Patenting perspective of modulators of ClpP endopeptidase: 2019-present

An Artificial Protein Modulator Reprogramming Neuronal Protein Functions

Targeting Caseinolytic Protease P and Its AAA1 Chaperone for Tuberculosis Treatment.

Anti-infective therapy using species-specific activators of Staphylococcus aureus ClpP

Caspase inhibitors: a review on recently patented compounds (2016-2023)

Recent advances in Clp protease modulation to address virulence, resistance and persistence of MRSA infection

Cathepsin B and L Inhibitors: a Patent Review (2010 - Present).

Therapeutic cysteine protease inhibitors: a patent review (2018–present)

An updated patent review of Akt inhibitors (2016-present)

The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders

An updated patent review of AKT inhibitors (2020 - present)

Molecular insights into the dynamic modulation of bacterial ClpP function and oligomerization by peptidomimetic boronate compounds

New insights into protein–protein interaction modulators in drug discovery and therapeutic advance

Discovery of CLPP-1071 as an Exceptionally Potent and Orally Efficacious Human ClpP Activator with Strong In Vivo Antitumor Activity

Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

Mechanism of allosteric activation in human mitochondrial ClpP protease

An update on the therapeutic potential of calpain inhibitors: a patent review

An Updated Patent Review of Mcl-1 Inhibitors (2020–2022)

Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present)

Homo-BacPROTAC-induced degradation of ClpC1 as a strategy against drug-resistant mycobacteria

Structural Insights into ClpP Protease Side Exit Pore-Opening by a Ph Drop Coupled with Substrate Hydrolysis.